Product Description
Mechanisms of Action: miR-122 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Santaris Pharma A/S
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis A|Hepatitis C, Chronic
Phase 1: Hepatitis C|Hepatitis C, Chronic|Hepatitis A
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01646489 |
SPC3649-206 | P1 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2012-09-01 |
2019-03-19 |
Treatments |
|
NCT00979927 |
SPC3649-202 | P1 |
Completed |
Hepatitis C |
2010-09-01 |
2019-03-19 |
Treatments |
|
NCT00688012 |
SPC3649-201 | P1 |
Completed |
Hepatitis C |
2009-05-01 |
2019-03-18 |
Treatments |
|
2010-019057-17 |
2010-019057-17 | P2 |
Completed |
Hepatitis C, Chronic |
2011-09-20 |
2022-03-13 |
||
NCT02031133 |
SPC3649-207E | P2 |
Unknown status |
Hepatitis C, Chronic|Hepatitis A |
2017-01-01 |
|||
NCT01872936 |
SPC3649-205 | P2 |
Unknown status |
Hepatitis C, Chronic|Hepatitis A |
2015-01-01 |
2019-03-19 |
Treatments |
|
NCT01727934 |
SPC3649-207 | P2 |
Unknown status |
Hepatitis C, Chronic|Hepatitis A |
2014-01-01 |
2019-03-19 |
Treatments |
|
NCT01200420 |
SPC3649-203 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2011-12-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/01/2023 |
PubMed |
MicroRNA-based therapeutics for inflammatory disorders of the microbiota-gut-brain axis. |
|
10/26/2021 |
PubMed |
Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer. |
|
06/30/2021 |
PubMed |
Role of non-coding RNAs in Dengue virus-host interaction. |